跳至主要内容
临床试验/NCT00157131
NCT00157131已完成3 期

A Study To Evaluate the Safety and Efficacy of Fibrin Sealant With 4IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated (FS 4IU VH S/D) to Adhere Tissues and Improve Wound Healing

Baxter Healthcare Corporation17 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2004年6月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
150
试验地点
17
主要终点
Adverse experiences (AEs) deemed possibly or probably related to treatment with FS 4IU VH S/D

研究概览

简要总结

The primary objective of this study is to evaluate skin graft adherence and wound healing in burn patients to evaluate whether FS 4IU VH S/D is equivalent or superior to the current standard of care (staples). The primary endpoint is achievement of complete (100%) wound closure within 28 days.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
— 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects or their legal representatives, who have read, understood and signed a written informed consent.
  • Subjects of either sex.
  • Female subjects of childbearing potential with a negative urine or serum pregnancy test on admission.
  • Subjects who are <= 65 years of age including pediatric subjects of all ages.
  • Subjects with total burn wounds measuring <= 40% TBSA.
  • Subjects with a contiguous deep partial thickness/full thickness wound, between 2% and 8% TBSA or two comparable, bilateral wounds each measuring between 1% and 4% TBSA.
  • Wounds designated as test sites require autologous sheet skin grafts with a thickness of 8/1000" - 16/1000"
  • Subjects who are able, and willing to comply with the procedures required by the protocol.

排除标准

  • Subjects with electrical burns.
  • Subjects with chemical burns
  • Digits and genitalia are excluded as test sites.
  • Subjects with infection at test area/test sites.
  • Subjects with test sites previously randomized and treated in this study.
  • Subjects with venous or arterial vascular disorder that directly affects a designated test area/test site.
  • Subjects with pre-existing hemolytic anemia
  • Subjects with diabetes mellitus.
  • Subjects with documented history of pathologically or pharmacologically induced immune deficiency.
  • Subjects judged to be chronically malnourished.
  • Subjects that are judged to have significant pulmonary compromise.
  • Subjects receiving systemic corticosteroids within 30 days prior to skin grafting (not including inhaled steroids).
  • Subjects with known or suspected hypersensitivity to bovine proteins.
  • Subjects participating in another clinical trial that is evaluating an unapproved drug or device.

结局指标

主要结局

Adverse experiences (AEs) deemed possibly or probably related to treatment with FS 4IU VH S/D

时间窗: 12 months after treatment

Complete wound closure by Day 28 after treatment with either FS 4IU VH S/D or staples as determined by a blinded independent review of the Day 28 photographs

时间窗: 28 days after treatment

次要结局

  • Presence of hematoma/seroma on Day 1(1 day after treatment)
  • Percent area of hematoma/seroma on Day 1(1 day after treatment)
  • 100% engraftment by Day 5(5 days after treatment)
  • Percent area of engraftment on Day 5(5 days after treatment)
  • Complete wound closure by Day 14(14 days after treatment)
  • Scar maturation assessed by blinded Vancouver Scar Scale evaluations on Months 3, 6, 9, and 12(3, 6, 9, and 12 months after treatment)
  • Percent area of closure by Days 14 and 28(14 and 28 days after treatment)

研究者

申办方类型
Industry

研究点 (17)

Loading locations...

相似试验